| Ytd | -46.71% | |
| 1y | -66.88% |
| Open | 3.90 | Prev Close | 3.88 | Low | 3.61 | High | 3.98 | Mkt Cap | 3.85M |
| Vol | 18.08K | Avg Vol | 61.97K | EPS | -48.13 | P/E | -0.08 | Forward P/E | -5.97 |
| Beta | 1.24 | Short Ratio | 0.50 | Inst. Own | 1.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.12 | 200-d Avg | 8.19 | 1yr Est | 20.00 |
RNAZ News
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-mark
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio
TransCode Therapeutics (NASDAQ: RNAZ) stockholders approved all proposals presented at the company's
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular
Gainers Innovative Eyewear (NASDAQ:LUCY) stock moved upwards by 95.4% to $1.49 during Monday's
TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus
Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis B
TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients;
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, sho
BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage c
BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage
BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and 4D Molecular Therapeutics (NASDAQ: FDMT
TransCode Therapeutics (NASDAQ: RNAZ - Get Free Report) and Karyopharm Therapeutics (NASDAQ: KPTI -
TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the pote
BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage
BOSTON, Feb. 5, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clin
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous
BOSTON , Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage
BOSTON , Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap
TransCode Therapeutics Inc. (NASDAQ: RNAZ - Get Free Report) shot up 0.9% on Friday. The stock trade
Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA
Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 month
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advan
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCo
Shares of Airspan Networks Holdings Inc. (NASDAQ: MIMO) shares rose sharply during Wednesday’s sessi
On Monday, 369 companies set new 52-week lows.
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.
During Tuesday's session, 275 companies made new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
During Thursday's session, 92 stocks hit new 52-week lows.
On Thursday, 148 companies set new 52-week lows.